View Older Stories View More Recent Stories
-
Increasing unusual put option volume: AMCR XIFR JCI HNGE MTSR GTM EWJ SLDP EWY ADMA TEVA
-
Teva Pharma (TEVA) Tops Q3 EPS by 10c, Offers Guidance
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Teva Pharma (TEVA) call put ratio 1.2 calls to 1 put
-
Teva Pharma (TEVA) PT Raised to $26 at UBS, 2030 Sales Estimate Increased
-
Truist on Teva Pharma (TEVA): 'We See Upside To Mgmt's Schizo Franchise Guide'
-
Goldman Sachs Reiterates Buy Rating on Teva Pharma (TEVA)
-
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
-
Truist on Teva Pharma (TEVA): 'BUY On Weakness'
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY25 Revenue Guidance
-
BofA Securities Reiterates Buy Rating on Teva Pharma (TEVA)
-
JPMorgan Reiterates Overweight Rating on Teva Pharma (TEVA)
-
Teva Pharma (TEVA) PT Lowered to $23 at UBS
-
Goldman Sachs Starts Teva Pharma (TEVA ) at Buy
-
Teva (TEVA) outlines acceleration path into a leading biopharma company
-
Truist Securities Starts Teva Pharma (TEVA) at Buy
-
JPMorgan Upgrades Teva Pharma (TEVA) to Overweight
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Teva Pharma (TEVA) Tops Q1 EPS by 4c; offers guidance
-
Teva Pharma (TEVA) call put ratio 2.2 calls to 1 put
-
Teva Pharma (TEVA) call put ratio 2.2 calls to 1 put into quarter results
-
Alvotech (ALVO) and Teva (TEVA) Announce FDA Approval of Interchangeability for SELARSDI with Stelara
-
Teva Pharma (TEVA) April 12.50 puts active on 32K contracts
-
Teva Pharma (TEVA) Announces FDA Filing Acceptance for AJOVY in Pediatric Episodic Migraine Prevention
-
Teva Pharma (TEVA) Reports Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749
-
Teva Pharma (TEVA) PT Lowered to $20 at BofA Securities
-
Teva (TEVA) and Medincell Announce FDA Acceptance of sNDA for UZEDY Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
-
Alvotech (ALVO) and Teva (TEVA) Announce SELARSDI Injection Now Available in the U.S.
-
Teva Pharma (TEVA) PT Lowered to $23 at BofA Securities
-
Teva Pharma (TEVA) Tops Q4 EPS by 2c, provides guidance
-
Stocks expected to have increasing option volume: TEVA CP NSC URI GLW HES ROK NOW WDC VFC LEVI V MA TMO CAT BX KLAC BX INTC TSCO SHW MO NOC CI
-
Teva Pharma (TEVA) call put ratio 1.2 calls to 1 put with focus on February calls into quarter results
-
Alvotech (ALVO) and Teva (TEVA) Announce Filing Acceptance of U.S. Biologics License Applications for AVT05
-
Teva Pharma (TEVA) PT Raised to $30 at UBS
-
Teva Pharma (TEVA) PT Raised to $30 at Piper Sandler
-
Catalyst Pharmaceuticals (CPRX) Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceuticals
-
Teva (TEVA) and Sanofi (SNY) Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
-
Piper Sandler Reiterates Overweight on Teva Pharma (TEVA) as Management Provides Updates
-
BofA Securities Reiterates Buy Rating on Teva Pharma (TEVA)
-
Increasing unusual put option volume: XLB XP WMB ACHR EMB VIPS HBAN AI KDP TEVA BE JBHT
-
Teva Pharma (TEVA) preader of 10K contracts of November 22 weekly 16 and December 27 weekly 16 puts
-
Teva Pharma (TEVA) Tops Q3 EPS by 3c; offers guidance
-
Teva Pharma (TEVA) option IV above 100 into quarter results and outlook
-
Teva Pharma (TEVA) call put ratio 1.7 calls to 1 put into quarter results
-
Teva Pharma (TEVA) Issues Statement on European Commission Decision; Company to Appeal
-
Teva Pharma (TEVA) PT Raised to $25 at Barclays
-
Lexaria Bioscience (LEXX): Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
-
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
-
Alvotech (ALVO) and Teva (TEVA) Announce U.S. FDA Approval of Additional Presentation of SELARSDI, Expanding its Label
